0000000000161353

AUTHOR

K. P. Singh

Estrogen-Induced Mutations and Its Role in the Development of Tumorigenesis

Using RAPD-PCR fingerprinting, the detection of mutations induced by estrogen (E) exposure was studied in nonmalignant- and malignant cells. Cells exposed to 17α-and 17β-estradiol, diethylstilbestrol, bisphenol A, and α-zearalanol induced mutations in different regions of the genome. They consisted of insertion/deletion as a result of point or length mutations and quantitative changes as a result of hypoploidy or polyploidy. We also detected several mutated loci in tumor-free tissues, adjacent to tumors, and DES-induced tumors. The data suggest that these mutations occurred in early stages of stilbene E-induced renal carcinogenesis, and that they may be induced as a result of stilbene E tre…

research product

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

research product